Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis - Ye, Shengtao; Chen, Junxin; Zheng, Ying; He, Mengmeng; Zhang, Yanqiu; Cheng, Yang; Leng, Yingrong; Wu, Enyi; Kong, Lingyi; Zhang, Hao (Cell death & disease, 2025)
Keywords: 13/109; 13/51; 13/89; 14/19; 14/35; 38/90; 631/67/1059/2326; 631/80/458; 64/60; 82/81; 82/83; Animals; Antibodies; Biochemistry; Biomedical and Life Sciences; Cancer; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - metabolism; Carcinoma, Hepatocellular - pathology; Cell Biology; Cell Culture; Cell Line, Tumor; Drug Resistance, Neoplasm - drug effects; Enzymatic activity; Enzymes; Ferroptosis; Ferroptosis - drug effects; Hepatocellular carcinoma; Humans; Immunology; Interferon regulatory factor 3; Life Sciences; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Mice; Mice, Nude; Nuclear Receptor Coactivators - genetics; Nuclear Receptor Coactivators - metabolism; Phenylurea Compounds; Pyridines; Sorafenib - pharmacology; Ubiquitin Thiolesterase - antagonists & inhibitors; Ubiquitin Thiolesterase - genetics; Ubiquitin Thiolesterase - metabolism; Ubiquitin-specific proteinase; USP18 protein